II-IIIB (T3N2) Resectable Non-small Cell Lung Cancer
1 clinical trials · Condition
◉ Watch II-IIIB (T3N2) Resectable Non-small Cell Lung Cancer
| Record | Firm | Date |
|---|---|---|
| Ivonescimab Monotherapy or in Combination With Chemotherapy as Neoadjuvant/Adjuvant Therapy for Resectable Non-small Cell Lung Cancer (NCT07241819) | Peking University Cancer Hospital & Institute | 2025-11-30 |
Track II-IIIB (T3N2) Resectable Non-small Cell Lung Cancer automatically
Every clearance here is in the API, with alerts when new ones post.